NCT07083362View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Study of HRS-8829

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions
Acute Ischemia Stroke
Interventions
DRUG

HRS-8829;Placebo

"Subject will receive HRS-8829 at dose level 1.~Subject will receive placebo at dose level 1."

DRUG

HRS-8829;Placebo

"Subject will receive HRS-8829 at dose level 2.~Subject will receive placebo at dose level 2."

DRUG

HRS-8829;Placebo

"Subject will receive HRS-8829 at dose level 3.~Subject will receive placebo at dose level 3."

DRUG

HRS-8829;Placebo

"Subject will receive HRS-8829 at dose level 4.~Subject will receive placebo at dose level 4."

Trial Locations (1)

100029

Beijing Anzhen Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY